Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases

AIM: To assess the risk of severe adverse events (AEs) within 6 months after treatment with biological agents in patients with rheumatic diseases (RD)/MATERIAL AND METHODS: The 6-month open-label trial included 107 patients with rheumatoid arthritis, antineutrophil cytoplasmic antibody-associated va...

ver descrição completa

Detalhes bibliográficos

Principais autores:	S V Moiseev, P I Novikov, E N Semenkova, L A Strizhakov, S V Guliaev, T N Ianushkevich, N V Nikiforova, A D Meshkov, V V Panasiuk, Iu D Sorokin, M V Taranova, S A Parfenova, L V Dubrovskaia, E S Zhabina, E I Kuznetsova, I A Lopatina, N M Bulanov, N A Mukhin
Formato:	Artigo
Idioma:	Russo
Publicado em:	"Consilium Medicum" Publishing house 2013-05-01
coleção:	Терапевтический архив
Assuntos:	genetically engineered biological agents rheumatic diseases vasculitis rheumatoid arthritis systemic lupus erythematosus safety efficiency
Acesso em linha:	https://ter-arkhiv.ru/0040-3660/article/view/31268
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!